Overview

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

Status:
Completed
Trial end date:
2011-07-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).
Phase:
Phase 2
Details
Lead Sponsor:
Furiex Pharmaceuticals, Inc
Treatments:
Eluxadoline